SCHEMBL22979112

SCHEMBL22979112

COc1cccc(-c2nc3c4ccccc4nc(NC4CN(C(=O)OCc5ccccc5)CCNC4=O)n3n2)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
THRB P10828 3/20 0.43
TP53 P04637 5/20 0.41
GAA P10253 2/20 0.41
ALPL P05186 1/20 0.41
LMNA P02545 2/20 0.41
HCRTR1 O43613 2/20 0.40
KMT2A Q03164 1/20 0.40
RXFP1 Q9HBX9 2/20 0.40
WNK1 Q9H4A3 1/20 0.40
ALDH1A1 P00352 2/20 0.39
TSHR P16473 1/20 0.39
ZAP70 P43403 1/20 0.39
SYK P43405 1/20 0.39
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29646395 1.00 MAPT (0.49) MAPTSMN1; SMN2THRBTP53GAA
SCHEMBL29648951 0.96 MAPT (0.46) MAPTSMN1; SMN2THRBTP53GAA
SCHEMBL29646384 0.92 MAPT (0.48) MAPTSMN1; SMN2THRBTP53GAA
SCHEMBL22979870 0.92 MAPT (0.48) MAPTSMN1; SMN2THRBTP53GAA
SCHEMBL22988038 0.92 MAPT (0.42) MAPTSMN1; SMN2THRBTP53LMNA
SCHEMBL22988118 0.91 MAPT (0.43) MAPTSMN1; SMN2THRBTP53GAA
SCHEMBL29646438 0.91 MAPT (0.43) MAPTSMN1; SMN2THRBTP53GAA
SCHEMBL29648986 0.91 MAPT (0.43) MAPTSMN1; SMN2THRBTP53GAA
SCHEMBL22988052 0.91 MAPT (0.42) MAPTSMN1; SMN2TP53GAAALPL
SCHEMBL22987541 0.91 MAPT (0.43) MAPTSMN1; SMN2THRBTP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 MAPT 4047/4885SMN1; SMN2 4234/4885THRB 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.